RA Capital Management, managed by Peter Kolchinsky, has revealed a new position in Repros Therapeutics Inc (NASDAQ:RPRX). RA Capital has disclosed a passive stake in the company, which amasses 6.2% of common stock, showed a new filing with the Securities and Exchange Commission. The position contains 1.44 million shares.
Repros Therapeutics Inc (NASDAQ:RPRX) is engaged in the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
For the three month period ended December 31, 2013, the company reported a net loss of $7.1 million, or $0.31 per share, compared to a net loss of $8.0 million, or $0.47 per share, for the same period in 2012. The decrease in net loss was primarily due to reduced clinical development expenses related to Androxal, partially offset by an increase in payroll and benefits expenses. For the 12-month period ended December 31, 2013, the company reported a net loss of $27.7 million, or $1.33 per share, compared to a net loss of $18.2 million, or $1.18 per share, for 2012.
Baker Bros. Advisors, managed by Julian Baker and Felix Baker, owns 2.78 million shares of Repros Therapeutics Inc (NASDAQ:RPRX). Another investor Jacob Gottlieb’s Visium Asset Management disclosed holding 1.84 million shares of the company at the end of the fourth quarter of 2013.
Boston-based RA Capital invests in companies with promising drugs and technologies. Last month, Ra Capital disclosed owning 2.43 million shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), equivalent to 14.6% of the common stock. In addition, the fund initiated a 7.2% passive stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX), the position amassing 750,000 shares. In January, Ra Capital reported selling a total of 300,000 shares of Derma Sciences Inc (NASDAQ:DSCI).